Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

Prompt treatment following traumatic brain injury (TBI) lowers risk of developing Alzheimer's disease (AD) in subsequent ...

Researchers at Brain Chemistry Labs, a state-of-the-art biology laboratory in Jackson, are studying the brains of dolphins in ...

New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...

Biogen and Eisai have announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an ...

Eli Lilly has received CDSCO approval for donanemab, an Alzheimer's treatment for adults in early symptomatic stages ...

Lilly’s donanemab receives CDSCO approval to treat early symptomatic Alzheimer’s disease: Our Bureau, Mumbai Tuesday, November 18, 2025, 14:15 Hrs [IST] Eli Lilly and Company ...

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline such as memory loss ...

Nanyang Technological University, Singapore (NTU Singapore) is leading 24 clinicians from the region and beyond to set up ...

On 12 November 2025, Bristol-Myers Squibb conducted a Phase 3 study to Evaluate the Efficacy and Safety of KarXT + KarX-EC ...

The DOC's existing health care provider, VitalCore, will operate the new hotline, as prison officials respond to six apparent suicides this year — compared to zero in 2024.